Parkinson’s disease news tops February coverage
Click Here to Manage Email Alerts
Developments in Parkinson’s disease — including biomarkers of progression and an FDA approval — topped Healio Neurology’s February coverage. Plus: new drug approval for relapsing MS, stroke incidence and concussions among football players.
Vision linked to cognitive decline, white matter degeneration in Parkinson’s disease
Patients with Parkinson’s disease and visual dysfunction had a higher risk for cognitive impairment and greater white matter degeneration compared with those without visual dysfunction, according to results published in Movement Disorders. Read more.
Gocovri receives FDA approval for second indication in Parkinson’s disease
The FDA approved Gocovri extended-release tablets for patients with Parkinson’s disease, marking the product’s second indication in the disease, according to a press release from Adamas Pharmaceuticals, the drug’s manufacturer. Read more.
FDA approves intramuscular formulation of Plegridy for relapsing forms of MS
The FDA has approved an intramuscular injection formulation of peginterferon beta-1a for use in patients with relapsing forms of MS, according to a press release from Biogen, the drug’s manufacturer. Read more.
Stroke incidence declines among older adults, remains steady among younger adults
Rates of ischemic stroke and intracerebral hemorrhage remained steady in adults aged 18 to 49 years while decreasing in older adults, particularly in those aged 70 years and older, according to results from a 13-year study. Read more.
Concussions, head impact exposure occur most often in football preseason, practices
Concussions and head impact exposure in college football players occurred at a “disproportionately higher” rate during the preseason vs. the regular season and most often happened in practices, not games. Read more.
Follow us on Twitter @HealioNeurology to stay in the loop with the latest developments in the field.